Result of AGM

RNS Number : 3751O

Instem plc

09 June 2022

 

Instem plc
("Instem" or the "Company")

Result of AGM

Instem  (AIM: INS.L), a leading provider of IT solutions to the global life sciences market, announces that at its Annual General Meeting held today, all resolutions were duly passed.   The results of the proxy voting position received in advance of the meeting are reported below:

No.	Resolution	For	% For	Against	% Against	Withheld
01	Accounts and Reports	13,886,707	89.98%	1,545,989	10.02%	2,094,614
02	Re-elect R A Bandali	17,527,120	100.00%	190	0.00%	0
03	Re-elect D M Sherwin	13,727,503	88.95%	1,705,343	11.05%	2,094,464
04	Re-elect M F McGoun	13,566,252	87.91%	1,866,594	12.09%	2,094,464
05	Re-appoint Auditors	17,527,120	100.00%	190	0.00%	0
06	Auditors Remuneration	17,527,310	100.00%	0	0.00%	0
07	Allot Shares	16,989,283	96.93%	538,027	3.07%	0
08	Allot Equity Securities	16,989,283	96.93%	538,027	3.07%	0
09	Make Market Purchases	17,527,310	100.00%	0	0.00%	0

Notes:

· The full text of each of the resolutions is contained in the Notice of Annual General Meeting dated 16 May 2022, which is available on the Company's website at https://www.instem.com .

· Proxy appointments which gave discretion to the Chairman of the AGM have been included in the "For" total for the appropriate resolution.

· A "Withheld" vote is not a vote in law and is not counted in the calculation of the proportion of the votes cast "For" or "Against" a resolution.

· The issued share capital of the Company as at 09 June 2022 was 22,676,808 ordinary shares of 10p each. No shares are held in treasury.

For further information, please contact:

Instem plc	Via Walbrook
Phil Reason, CEO
Nigel Goldsmith, CFO
Singer Capital Markets (Nominated Adviser & Broker)	[phone]
Peter Steel Alex Bond Rachel Hayes
Stifel Nicolaus Europe Limited (Joint Broker)	[phone]
Ben Maddison
Alex Price
Walbrook Financial PR	[phone]
Tom Cooper	[e-mail]
Nick Rome

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management, Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based Insight Generation.

Instem solutions are in use by over 700 customers worldwide, including all of the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform during their development.

To learn more about Instem solutions and its mission, please visit  www.instem.com

 

END

 

 

RAGSSWFLUEESEIM